US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

40.00

+0.47041.19%

Volume:778

Turnover:31.14K

Market Cap:8.00M

PE:- -

High:40.04

Open:40.04

Low:40.00

Close:39.53

52wk High:43.01

52wk Low:24.78

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.63

T/O Rate:0.39%

Dividend:0.32

Dividend Rate:0.80%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Praxis Precision Medicines Grants 7,318 RSUs to 29 New Employees Under 2024 Inducement Plan

Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030

THOMSON REUTERS

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

THOMSON REUTERS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Dianthus Therapeutics Inc Q2 Operating Expenses USD 62.243 Million

THOMSON REUTERS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Inc Expected to Post a Loss of $3.66 a Share - Earnings Preview

Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027

THOMSON REUTERS

Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases

THOMSON REUTERS

Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps

THOMSON REUTERS

Early Backer of Humanoid Robot Startup Sets Sights on Chengdu Brain-Computer Interface Company

New Standards Set to Boost Industry Growth and Consumer Wellbeing

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview

Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award

Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IBRN/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":40.0001,"timestamp":1787682689953,"preClose":39.5297,"halted":0,"volume":778,"delay":0,"changeRate":0.011899913229799493,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Trading","change":0.4704,"latestTime":"08-25 14:34:05 EDT","open":40.04,"high":40.04,"low":40.0001,"amount":31142.169887999997,"amplitude":0.001009,"askPrice":40.17,"askSize":300,"bidPrice":39.89,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":39.5297,"sharesOutstanding":150000,"nav":39.601587,"aum":7920317.4,"dividendRate":0.008027,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.45,"preClose":39.5297,"latestTime":"16:10 EDT","volume":6,"amount":237.1782,"timestamp":1787602204712,"change":-0.0797,"changeRate":-0.002016,"amplitude":0},"volumeRatio":0.626382,"impliedVol":0.1031,"impliedVolPercentile":0.6096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.626382,"shares":200000,"dividePrice":0.3211,"high":40.04,"amplitude":0.001009,"preClose":39.5297,"low":40.0001,"week52Low":24.78,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":40.0001,"eps":0,"divideRate":0.008027,"volume":778,"delay":0,"ttmEps":0,"open":40.04,"prevYearClose":32.3193,"prevWeekClose":39.6482,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":39.7665,"twentyDayClose":37.4412,"sixtyDayClose":35.6957},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657567780","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567780?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:20","pubTimestamp":1785878408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Viridian Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LU0128526141.USD","BK4585","BK4139","LABU","DNTH","LU0029874061.USD","XBI","BK4137","BK4588","HCSG","IBRN","BK4581","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569783","title":"Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569783?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874166,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Q2 net loss widens as R&D costs riseOverviewUS biotech firm reported Q2 net loss widened to $50.2 mlnOperating expenses for Q2 rose, driven by higher R&D costs for clinical progr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","PVLA","BK4539","BK4505","KROS","IBRN","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693385","title":"Praxis Precision Medicines Grants 7,318 RSUs to 29 New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693385?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873760,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement planPraxis Precision Medicines granted restricted stock units covering 7,318 common shares to 29 new non-executiv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL2Gq3xh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","IE00BJT1NW94.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","IE0002141913.USD","LU0889565916.HKD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","PRAX","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","IBRN","IE00BN0W2W23.USD","BK4139","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","LU0109394709.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657856473","title":"Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2657856473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657856473?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA59Z0BL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756986","title":"Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756986?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA59Z0BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657791566","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657791566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657791566?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUABCBZ25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0109394709.USD","PRAX","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","IBRN","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657737566","title":"Dianthus Therapeutics Inc Q2 Operating Expenses USD 62.243 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657737566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657737566?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXJKZ0MB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657678635","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657678635","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657678635?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"Investor Contact:. 857-702-9452. Media Contact:. Dan Ferry. LifeSci Advisors. 617-430-7576","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338776/0/en/Praxis-Precision-Medicines-Inc-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PRAX","IE00BFTCPJ56.SGD","CNS","LU0109394709.USD","IBRN","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LCLG","LU0320765992.SGD","BK4561","IE00B4R5TH58.HKD","BK4135","LU0889565916.HKD","ASO","BK4139","IE00BJT1NW94.SGD","BK4200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656590215","title":"Praxis Precision Medicines Inc Expected to Post a Loss of $3.66 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656590215","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656590215?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:18","pubTimestamp":1785849486,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc <PRAX.OQ> expected to post a loss of $3.66 a share - Earnings PreviewPraxis Precision Medicines IncPRAX.OQPRAX.Ois expected to  show no change in quarterly revenue when ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","IBRN","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4139","IE00B4R5TH58.HKD","LU0109394709.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753021","title":"Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753021?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553079","title":"Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553079?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530762","title":"Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530762?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100243579","title":"Early Backer of Humanoid Robot Startup Sets Sights on Chengdu Brain-Computer Interface Company","url":"https://stock-news.laohu8.com/highlight/detail?id=1100243579","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100243579?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:14","pubTimestamp":1785838478,"startTime":"0","endTime":"0","summary":"Wabo Technology Co., Ltd. recently announced the completion of its angel round of financing, featuring a notably prestigious lineup of investors. Participants include Vertex Ventures, under...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","688836","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148426331","title":"New Standards Set to Boost Industry Growth and Consumer Wellbeing","url":"https://stock-news.laohu8.com/highlight/detail?id=1148426331","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148426331?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:40","pubTimestamp":1785800457,"startTime":"0","endTime":"0","summary":"Starting August 1, a total of 488 national standards, including 46 mandatory ones and 442 recommended ones, will be implemented, as announced by the State Administration for Market Regulation...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVR","BK4020","IVRS","GNSS","MAKX","RAYS","MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300056","title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300056","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300056?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:10","pubTimestamp":1785798604,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $98,821.72David Joseph Gaffin, EVP and chief legal officer, sold 2,034 ordinary shares on Aug. 3, 2026 at USD 48.58.His direct stake fell t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9zXC08:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","ALKS","MEDX","IBRN","BK4139","PSIL","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300873","title":"Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300873","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300873?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:12","pubTimestamp":1785795140,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc <DNTH.OQ> expected to post a loss of86cents a share - Earnings PreviewDianthus Therapeutics IncDNTH.OQDNTH.Ois expected to  show a rise in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656062307","title":"Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2656062307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656062307?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:00","pubTimestamp":1785794413,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics grants 87,000 inducement stock options at $106.02 per shareDianthus Therapeutics granted inducement equity awards on Aug. 3, 2026 to six newly hired non-executive employees.Non-q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3J16cY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","DNTH","LU2210150020.SGD","BCDF","SG9999014013.SGD","BK4588","SG9999014021.USD","IBRN","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036307","title":"Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036307?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:00","pubTimestamp":1785794400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA59RRJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656019363","title":"Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2656019363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656019363?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:09","pubTimestamp":1785787780,"startTime":"0","endTime":"0","summary":"Alkermes amends 8-K to disclose CEO Blair Jackson pay package including $5 million equity awardAlkermes amended a Feb. 25 Form 8-K on its CEO succession to add previously undetermined compensation ter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL2dlwWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","FBT","PSCH","MEDX","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303694","title":"Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303694?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:32","pubTimestamp":1785774777,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. ($PRAX) announced an update on their ongoing clinical study. Praxis Precision Medicines is running an extension st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-extends-vormatrogine-epilepsy-trial-keeping-long-term-growth-story-in-play?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-extends-vormatrogine-epilepsy-trial-keeping-long-term-growth-story-in-play?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU0889565916.HKD","IBRN","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE0009355771.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","PRAX","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}